A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.
Novel strategies are required to provide rapid vaccine coverage in the event of an influenza pandemic. A phase I/II dose finding/formulation study was performed with a whole-virus H5N1 clade 1 A/Vietnam vaccine (2-dose priming regimen) to evaluate safety and immunogenicity. Seventy-seven of 141 subjects in this study received a booster (12-17 months after priming) with a 7.5-microg dose of a clade 2.1 A/Indonesia vaccine. The prime-boost regimen resulted in antibody responses against clade 1, 2.1, 2.2, and 2.3 viruses that were significantly higher than those after the priming regimen. These findings demonstrate that a prime-boost regimen may alleviate vaccine supply constraints in a pandemic.
Ehrlich
Hartmut J
HJ
Global R&D, Baxter BioScience, Vienna, Austria.
Müller
Markus
M
Fritsch
Sandor
S
Zeitlinger
Markus
M
Berezuk
Greg
G
Löw-Baselli
Alexandra
A
van der Velden
Maikel V W
MV
Pöllabauer
Eva Maria
EM
Maritsch
Friedrich
F
Pavlova
Borislava G
BG
Tambyah
Paul A
PA
Oh
Helen M L
HM
Montomoli
Emanuele
E
Kistner
Otfried
O
Noel Barrett
P
P
D000818:Animals; D000914:Antibodies, Viral; D002522:Chlorocebus aethiops; D004306:Dose-Response Relationship, Immunologic; D006801:Humans; D007117:Immunization, Secondary; D007156:Immunologic Memory; D053124:Influenza A Virus, H5N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology*; D007251:Influenza, Human / Q000517:prevention & control; D014709:Vero Cells
D000914:Antibodies, Viral; D007252:Influenza Vaccines